To systematically map the drug-combination landscape of TEADi in Hippo-deficient mesothelioma, we performed a high-throughput combinatorial drug-screening between the TEADi VT-103 and an entire collection of about 2800, mechanistically annotated, oncology-focused drugs (MIPE 6.0 library, Mechanism Interrogation PlatEs version 6.0) in NCI-H226 (NF2-deficient) and NCI-2052 (NF2-mutant) cell lines. Here, NF2 is linked to mesothelioma.